BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 29934374)

  • 1. Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone.
    Young LH; Viscoli CM; Schwartz GG; Inzucchi SE; Curtis JP; Gorman MJ; Furie KL; Conwit R; Spatz ES; Lovejoy A; Abbott JD; Jacoby DL; Kolansky DM; Ling FS; Pfau SE; Kernan WN;
    Circulation; 2018 Sep; 138(12):1210-1220. PubMed ID: 29934374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke).
    Yaghi S; Furie KL; Viscoli CM; Kamel H; Gorman M; Dearborn J; Young LH; Inzucchi SE; Lovejoy AM; Kasner SE; Conwit R; Kernan WN;
    Circulation; 2018 Jan; 137(5):455-463. PubMed ID: 29084736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus.
    Young LH; Viscoli CM; Curtis JP; Inzucchi SE; Schwartz GG; Lovejoy AM; Furie KL; Gorman MJ; Conwit R; Abbott JD; Jacoby DL; Kolansky DM; Pfau SE; Ling FS; Kernan WN;
    Circulation; 2017 May; 135(20):1882-1893. PubMed ID: 28246237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial.
    Spence JD; Viscoli CM; Inzucchi SE; Dearborn-Tomazos J; Ford GA; Gorman M; Furie KL; Lovejoy AM; Young LH; Kernan WN;
    JAMA Neurol; 2019 May; 76(5):526-535. PubMed ID: 30734043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
    Kernan WN; Viscoli CM; Furie KL; Young LH; Inzucchi SE; Gorman M; Guarino PD; Lovejoy AM; Peduzzi PN; Conwit R; Brass LM; Schwartz GG; Adams HP; Berger L; Carolei A; Clark W; Coull B; Ford GA; Kleindorfer D; O'Leary JR; Parsons MW; Ringleb P; Sen S; Spence JD; Tanne D; Wang D; Winder TR;
    N Engl J Med; 2016 Apr; 374(14):1321-31. PubMed ID: 26886418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction.
    Kernan WN; Viscoli CM; Dearborn JL; Kent DM; Conwit R; Fayad P; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Stuart A; Young LH;
    JAMA Neurol; 2017 Nov; 74(11):1319-1327. PubMed ID: 28975241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial.
    Furie KL; Viscoli CM; Gorman M; Ford GA; Young LH; Inzucchi SE; Guarino PD; Lovejoy AM; Conwit R; Tanne D; Kernan WN;
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):21-27. PubMed ID: 28939682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial.
    Viscoli CM; Brass LM; Carolei A; Conwit R; Ford GA; Furie KL; Gorman M; Guarino PD; Inzucchi SE; Lovejoy AM; Parsons MW; Peduzzi PN; Ringleb PA; Schwartz GG; Spence JD; Tanne D; Young LH; Kernan WN;
    Am Heart J; 2014 Dec; 168(6):823-9.e6. PubMed ID: 25458644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of lower doses of pioglitazone after stroke or transient ischaemic attack in patients with insulin resistance.
    Spence JD; Viscoli C; Kernan WN; Young LH; Furie K; DeFronzo R; Abdul-Ghani M; Dandona P; Inzucchi SE
    Diabetes Obes Metab; 2022 Jun; 24(6):1150-1158. PubMed ID: 35253334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to study drug in a stroke prevention trial"?>.
    Kiran A; Viscoli CM; Furie KL; Gorman M; Kernan WN
    J Stroke Cerebrovasc Dis; 2020 Oct; 29(10):105048. PubMed ID: 32912514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease.
    Inzucchi SE; Viscoli CM; Young LH; Furie KL; Gorman M; Lovejoy AM; Dagogo-Jack S; Ismail-Beigi F; Korytkowski MT; Pratley RE; Schwartz GG; Kernan WN;
    Diabetes Care; 2016 Oct; 39(10):1684-92. PubMed ID: 27465265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taking care of volunteers in a stroke trial: a new assisted-management strategy.
    Stuart AC; Sico JJ; Viscoli CM; Tayal AH; Inzucchi SE; Ford GA; Furie KL; Cote R; Spence JD; Tanne D; Kernan WN
    Stroke Vasc Neurol; 2016 Sep; 1(3):108-114. PubMed ID: 28959471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke.
    Kernan WN; Inzucchi SE; Viscoli CM; Brass LM; Bravata DM; Shulman GI; McVeety JC; Horwitz RI
    Stroke; 2003 Jun; 34(6):1431-6. PubMed ID: 12730556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lobeglitazone, a novel thiazolidinedione, for secondary prevention in patients with ischemic stroke: a nationwide nested case-control study.
    Yoo J; Jeon J; Baik M; Kim J
    Cardiovasc Diabetol; 2023 May; 22(1):106. PubMed ID: 37147722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case-control study.
    Woo MH; Lee HS; Kim J
    Cardiovasc Diabetol; 2019 May; 18(1):67. PubMed ID: 31151454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    McGuire DK; Alexander JH; Johansen OE; Perkovic V; Rosenstock J; Cooper ME; Wanner C; Kahn SE; Toto RD; Zinman B; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; Marx N;
    Circulation; 2019 Jan; 139(3):351-361. PubMed ID: 30586723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction.
    Furtado RHM; Bonaca MP; Raz I; Zelniker TA; Mosenzon O; Cahn A; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Nicolau JC; Gause-Nilsson IAM; Fredriksson M; Langkilde AM; Sabatine MS; Wiviott SD
    Circulation; 2019 May; 139(22):2516-2527. PubMed ID: 30882239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program.
    Rådholm K; Figtree G; Perkovic V; Solomon SD; Mahaffey KW; de Zeeuw D; Fulcher G; Barrett TD; Shaw W; Desai M; Matthews DR; Neal B
    Circulation; 2018 Jul; 138(5):458-468. PubMed ID: 29526832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study.
    Hung YC; Chiu LT; Huang HY; Bau DT
    Cardiovasc Diabetol; 2020 Jun; 19(1):94. PubMed ID: 32563247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.
    Viscoli CM; Inzucchi SE; Young LH; Insogna KL; Conwit R; Furie KL; Gorman M; Kelly MA; Lovejoy AM; Kernan WN;
    J Clin Endocrinol Metab; 2017 Mar; 102(3):914-922. PubMed ID: 27935736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.